{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-23-000065","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.385518+00:00","generated_at":"2026-06-10T04:26:51.955026+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Neurocrine's crinecerfont Phase 3 pediatric CAH study meets primary, key secondary endpoints","bullets":["Primary endpoint: statistically significant decrease in serum androstenedione at Week 4 vs placebo (p=0.0002).","Key secondary: significant reduction in daily glucocorticoid dose while maintaining androgen control at Week 28 vs placebo (p<0.0001).","About 30% of crinecerfont patients achieved reduction to physiologic GC dose vs 0% placebo.","Drug generally well-tolerated; common AEs: headache, fever, vomiting, URI, nasopharyngitis.","Data to support FDA submission in 2024, with EMA submission to follow."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-23-000065","json":"https://secwatch.observer/filing/0000914475-23-000065.json","markdown":"https://secwatch.observer/filing/0000914475-23-000065.md","text":"https://secwatch.observer/filing/0000914475-23-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000065/0000914475-23-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000065/nbix-20231005.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:26:51.955026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}